Brokerages Set CRISPR Therapeutics AG (NASDAQ:CRSP) Price Target at $77.93

CRISPR Therapeutics AG (NASDAQ:CRSP) has earned an average rating of “Hold” from the eighteen analysts that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $77.93.

Several equities research analysts recently commented on the company. Barclays reduced their price objective on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a report on Wednesday, November 6th. Royal Bank of Canada restated a “sector perform” rating and set a $53.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Chardan Capital reiterated a “buy” rating and set a $94.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday, December 10th. JMP Securities restated a “market outperform” rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a research note on Friday, December 20th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $84.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th.

CRISPR Therapeutics Stock Performance

CRSP stock opened at $38.65 on Friday. The firm has a 50 day moving average price of $47.48 and a 200-day moving average price of $49.76. CRISPR Therapeutics has a 52-week low of $38.20 and a 52-week high of $91.10. The firm has a market capitalization of $3.30 billion, a price-to-earnings ratio of -13.66 and a beta of 1.62.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The company had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. During the same period in the prior year, the firm posted ($1.41) EPS. As a group, sell-side analysts forecast that CRISPR Therapeutics will post -5.13 earnings per share for the current fiscal year.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 30,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $55.62, for a total value of $1,668,600.00. Following the completion of the transaction, the chief executive officer now owns 196,540 shares in the company, valued at approximately $10,931,554.80. The trade was a 13.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the sale, the general counsel now owns 62,597 shares in the company, valued at $2,896,989.16. The trade was a 1.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,382 shares of company stock valued at $2,744,179 in the last ninety days. Corporate insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CRSP. SFE Investment Counsel grew its stake in shares of CRISPR Therapeutics by 3.6% during the second quarter. SFE Investment Counsel now owns 5,846 shares of the company’s stock valued at $316,000 after buying an additional 203 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its position in CRISPR Therapeutics by 4.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 4,606 shares of the company’s stock valued at $249,000 after acquiring an additional 211 shares during the last quarter. Boston Family Office LLC increased its stake in CRISPR Therapeutics by 2.2% in the third quarter. Boston Family Office LLC now owns 9,763 shares of the company’s stock worth $459,000 after purchasing an additional 213 shares during the period. Bedell Frazier Investment Counselling LLC lifted its position in shares of CRISPR Therapeutics by 0.8% during the third quarter. Bedell Frazier Investment Counselling LLC now owns 26,357 shares of the company’s stock worth $1,238,000 after purchasing an additional 218 shares during the last quarter. Finally, National Bank of Canada FI boosted its stake in shares of CRISPR Therapeutics by 35.0% during the second quarter. National Bank of Canada FI now owns 848 shares of the company’s stock valued at $46,000 after purchasing an additional 220 shares during the period. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.